In addition to assuming sole responsibility for the costs of development and commercialization of AN2690, Schering-Plough is obligated to make payments to us of up to $505 million if certain development, regulatory and commercial milestones for onychomycosis are met. According to an Anacor press release, " Schering-Plough paid us a $40 million, non-refundable, non-creditable up-front fee in March 2007, and we have the right to require Schering-Plough to purchase up to $10 million of our capital stock. Schering-Plough and Anacor – In February 2007 Schering-Plough entered into a development and commercialization alliance with Anacor for an antifungal known as AN2690. No initial payments will be made by either party." Select Joint Ventures, Partnerships and Alliances with Small Pharma Īccording to Medical News Today, "Novartis and Schering-Plough will share the costs of developing the indacaterol-mometasone combination product. Schering-Plough and Novartis – Are involved in a development and commercialization alliance to produce a new fixed-dose combination asthma medication to compete with GSK and AstraZeneca in a market predicted to reach $12.2 billion by 2015. According to an SEC 8-K report, "Schering-Plough and Bayer will share Bayer's portion of the profits on the U.S. Schering-Plough, Bayer, and GlaxoSmithKline – Levitra – Schering-Plough and GSK market Levitra, developed by Bayer and GSK, in the United States following Schering-Plough and Bayer AG's commercialization alliance in September 2004. Schering-Plough and Novo Nordisk – Prandin – In January 1998, these two companies signed a multi-year commercialization alliance for Novo Nordisk's oral anti-diabetic agent, Prandin. market leader both in patient share and dollar share for GP IIb- IIIa inhibitors, with approximately 71 percent and 56 percent, respectively, of the U.S. Based on recent third party audit reports for August 2003, INTEGRILIN continues to be the U.S. product sales and Schering-Plough pays Millennium royalties on sales outside of the U.S. Millennium-Schering sales force for INTEGRILIN® (eptifibatide) Injection Both parties share the revenue and expenses related to U.S. Worldwide sales of INTEGRILIN for the quarter ended Septemwere $79.2 million, as provided to Millennium by Schering-Plough Corporation. Millennium's 2003 third quarter report states that "Co-promotion revenue, based on worldwide sales of INTEGRILIN® (eptifibatide) Injection, was $47.9 million for the quarter ended September 30, 2003, compared to $45.0 million for the same period in 2002. As of July 2005, Schering-Plough exclusively develops and commercializes INTEGRILIN in areas outside of Europe and pays Millennium royalties. Schering-Plough and Millenium – In July 2005 the two companies restructured a pre-existing partnership. In addition, the agreement gives Bayer rights to promote certain Schering-Plough cancer products in the United States and key European markets for a defined period of time in order to supplement efforts by Schering-Plough's oncology salespeople. In Japan, Schering-Plough's and Bayer's local organizations will co-promote Schering-Plough's cholesterol treatment ZETIA, but will otherwise remain independent.
A substantial number of high-performing Bayer sales representatives and marketing personnel are expected to be integrated into Schering-Plough's pharmaceutical organization in the United States and Puerto Rico." Schering-Plough and Bayer will share Bayer's portion of the profits on the U.S. commercialization activities for the erectile dysfunction medicine LEVITRA under Bayer's existing global co-promotion agreement and will jointly manage the business in the United States with GlaxoSmithKline PLC. Schering-Plough will also understake Bayer's U.S. Schering-Plough will pay Bayer a substantial royalty based on net sales of these products. According to a Schering-Plough press release, "Schering-Plough will undertake Bayer's marketing and sales activities in the United States and Puerto Rico for all of its primary care products, including AVELOX and CIPRO in the antibiotics category, the cardiovascular product ADALAT (nifedipine) and some other smaller, established primary care Bayer products. Schering-Plough and Bayer – In September 2004 Bayer HeathCare entered into a strategic alliance with Schering-Plough, under the terms of which Bayer's primary care pharmaceutical products are to be marketed and distributed by Schering-Plough in the United States. Select Joint Ventures, Partnerships, and Alliances with Big Pharma
0 kommentar(er)
